Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study

Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study

Author Mansur, Rodrigo Barbachan Autor UNIFESP Google Scholar
Ahmed, Juhie Google Scholar
Cha, Danielle S. Google Scholar
Woldeyohannes, Hanna O. Google Scholar
Subramaniapillai, Mehala Google Scholar
Lovshin, Julie Google Scholar
Lee, Jung G. Google Scholar
Lee, Jae-Hon Google Scholar
Brietzke, Elisa Autor UNIFESP Google Scholar
Reininghaus, Eva Z. Google Scholar
Sim, Kang Google Scholar
Vinberg, Maj Google Scholar
Rasgon, Natalie Google Scholar
Hajek, Tomas Google Scholar
McIntyre, Roger S. Google Scholar
Abstract Background: There is a paucity of treatments that are capable of reliably and robustly improving cognitive function in adults with mood disorders. Glucagon-like peptide-1 is synthesized centrally and its receptors are abundantly expressed in neural circuits subserving cognitive function. We aimed to determine the effects of liraglutide, a GLP-1 receptor (GLP-1 R) agonist, on objective measures of cognition in adults with a depressive or bipolar disorder. Methods: In this 4-week, pilot, open-label, domain-based study (e.g. cognition), we recruited 19 individuals with major depressive disorder (MDD) or bipolar disorder (BD) and an impairment in executive function. defined as a below-average performance in the Trail Making Test-B (TMTB). Liraglutide 1.8 mg/day was added as an adjunct to existing pharmacotherapy. Results: Participants had significant increases from baseline to week 4 in the TMTB standard score (age am education corrected) (Cohen's d=0.64, p=0.009) and in a composite Z-score comprising multiple cognitive tests (i.e. Digit Symbol Substitution Test, Rey Auditory Verbal Learning Test, Stroop test) (Cohen's d=0.77, p < 0.001). Neither changes in mood rating scales nor metabolic parameters were associated with changes in cognitive performance (all p > 0.05)

however baseline insulin resistance (IR) and body mass index (BMI

moderated the changes in the composite Z-score (p=0.021 and p=0.046, respectively), indicating larger responses in individuals with higher IR and BMI at baseline. There was a significant increase in lipase (p < 0.001), but individual values were above the upper limit of normality. Limitations: Small sample size, open-label design, lack of a placebo group. Conclusions: Liraglutide was safe and well tolerated by a sample of non-diabetic individuals with mood disorders and had beneficial effects on objective measures of cognitive function. Larger studies with controlled trial designs are necessary to confirm and expand the results described herein.
Keywords Major depressive disorder
Bipolar disorder
Glucagon-like peptide-1
Insulin resistance
xmlui.dri2xhtml.METS-1.0.item-coverage Amsterdam
Language English
Date 2017
Published in Journal Of Affective Disorders. Amsterdam, v. 207, p. 114-120, 2017.
ISSN 0165-0327 (Sherpa/Romeo, impact factor)
Publisher Elsevier Science Bv
Extent 114-120
Access rights Closed access
Type Article
Web of Science ID WOS:000389088600017

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account